Stock investment tips.

So certain events have occurred and I've decided to be a millionaire instead of a nurse, mainly to avoid any misunderstandings, since any misunderstandings would be big misunderstandings.

Anyway, I have my flaws, people misunderstand me, which I believe I have mentioned, perhaps I also am impatient and prefer to go my own way when learning things and end up out of the loop, not using the right terms and lingo, however on the plus side I have often been called a good judge of people/character and I believe I am quite competent and intelligent when I am committed.

What would be the absolute raw basics of investment then? I believe that I have the potential to become exceptional if I apply my finely honed reasoning skills to this task. I shall have my million in no time.

>>49
>>51
>>56
' >Primary product is an FDA approved drug ORTHOVISC, used for osteoarthritis, joints cartilage regeneration ect. They have a long lineup of other drugs and products as well, but the first one is their biggest cash cow.

I guess most of that information is from their SEC filings but a few searches reveals that orthovisc has a few competitors. How did you find out that doctors receive a "mark up" for prescribing it?

Their SPO profile says this.

http://access.edgar-online.com/ipo.aspx?colleft=613ecf6a-b2a7-4b42-a0c8-809161372aec&colright=76baaeb6-2549-44f5-8e1d-cd700701e704&cikid=217&tabindex=2&coname=anika%20therapeutics%20inc&fnid=9608&ipo=0

' >The Company believes its expertise and proprietary know-how in the development and manufacture of ultra-pure, high molecular weight HA products are difficult to replicate and provide it with a competitive advantage.

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=8903875-56504-101153&type=sect&dcn=0001157523-12-005906

Averaging $10 million every quarter, they also have variants of the product so they must use the same technological "competitive advantage" to dominate these markets, apparently they have a dermal range but that isn't as useful as different kinds of medicine. I estimate their advantage accounts for around $13 million per quarter.

http://finance.yahoo.com/q/ks?s=ANIK+Key+Statistics
Revenue (ttm):    67.20M
Net Income Avl to Common (ttm):    10.18M
10.18/67.2= around 15% of their revenue is kept as income after expenses, tax, interest, etc..

So a rough estimate of their lowest after-tax annual income is $7.9 million, this is a worst case scenario, it is far more likely to be higher. Last year when their share price hovered around 14.5 they were making similar amounts of money before their debaucle with the delayed orthovisc orders and later FDA rejection.

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=8755528-10359-14346&type=sect&dcn=0001157523-12-004339
Three Months Ended June 30
Net income $3,736,868
Comprehensive income $2,136,664

I guess that confirms they were undervalued somewhat and the stock market will timidly come back to Anika.

Their report is in with record quarterly earnings and we will see how the stock market reacts now.

http://www.nasdaq.com/article/anika-therapeutics-reports-fourth-quarter-and-full-year-2012-financial-results-20130227-01483#.US8iPTveIus